In a more recent study by Gibson et al. (2021), exploring real-world clinical outcomes of patients with ALK-rearranged advanced NSCLC treated with alectinib or crizotinib in Alberta, Canada, the mPFS was 16 months for crizotinib and 34.9 months for alectinib, while the mOS was 46.6 months for crizotinib and 50.7 months for alectinib [47]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.